Skip header and navigation

Refine By

   MORE

8 records – page 1 of 1.

Cellular source and role of adenosine in isoproterenol-induced coronary vasodilatation.

https://arctichealth.org/en/permalink/ahliterature11978
Source
J Mol Cell Cardiol. 1991 Oct;23(10):1137-48
Publication Type
Article
Date
Oct-1991
Author
M J Pekka Raatikainen
K J Peuhkurinen
I E Hassinen
Author Affiliation
Department of Medical Biochemistry, University of Oulu, Finland.
Source
J Mol Cell Cardiol. 1991 Oct;23(10):1137-48
Date
Oct-1991
Language
English
Publication Type
Article
Keywords
Adenosine - metabolism - pharmacology
Adenosine Triphosphate - metabolism
Animals
Coronary Circulation - drug effects
Coronary Vessels - drug effects - metabolism
Endothelium, Vascular - cytology - drug effects - metabolism
Hypoxanthine
Hypoxanthines - metabolism
Inosine - metabolism
Isoproterenol - pharmacology
Male
Myocardium - metabolism
Oxygen Consumption - drug effects
Phosphorylation
Rats
Rats, Inbred Strains
Research Support, Non-U.S. Gov't
Vasodilation - drug effects - physiology
Xanthine
Xanthines - metabolism
Abstract
The role of adenosine and its cellular source in isoproterenol-induced coronary vasodilatation was investigated in isolated perfused rat hearts prelabelled with [3H]adenosine. Time courses (times for half-maximal increase) were measured for changes in oxygen consumption (2.23 +/- 0.22 min), coronary flow (3.30 +/- 0.33 min), concentrations of effluent radioactivity (3.92 +/- 0.30 min) and adenosine and its metabolites (inosine, hypoxanthine and xanthine) (2.00 +/- 0.23 min). Isoproterenol stimulation decreased the cellular energy state and increased the concentration of tissue adenosine and its metabolites. Coronary flow was linearly correlated with tissue adenosine (r = 0.85) and phosphorylation potential (r = -0.82) and tissue adenosine also showed a linear correlation with phosphorylation potential (r = -0.84) and tissue free [AMP] (r = 0.79). The specific radioactivities of tissue nucleotides remained constant, but those of adenosine, inosine and hypoxanthine + xanthine were decreased by 42%, 26% and 46%, respectively. Purine compound concentrations increased during isoproterenol stimulation from basal values of 56 +/- 23, 98 +/- 33 and 44 +/- 19 nM to 388 +/- 173, 583 +/- 156 and 178 +/- 27 nM, respectively. The basal specific radioactivity ratio of adenosine:inosine:(hypoxanthine + xanthine) in the effluent perfusate was 1:0.5:7, but the specific radioactivities decreased rapidly upon isoproterenol stimulation, and at 3 min the ratio had changed to 1:2.5:16.5. The time courses of release and the changes in the specific radioactivities of the nucleosides indicate that adenosine release occurred mainly from cardiomyocytes, and that the release of adenosine and its metabolites from the cardiomyocytes preceded that from the endothelium. It is also shown that adenosine release during catecholamine stimulation occurs concomitantly with a decrease in the cellular energy state and AMP accumulation. This is in accord with the adenosine hypothesis of coronary vasoregulation.
PubMed ID
1749005 View in PubMed
Less detail

[How do I diagnose and treat ventricular extrasystoles?]

https://arctichealth.org/en/permalink/ahliterature53670
Source
Duodecim. 2002;118(2):145-54; quiz 154, 208
Publication Type
Article
Date
2002
Author
M J Pekka Raatikainen
Sinikka Yli-Mäyry
Heikki V Huikuri
Author Affiliation
OYS:n sisätautien klinikka, kardiologian osasto Kajaanintie 50 90220 Oulu. pekka.raatikainen@oulu.fi
Source
Duodecim. 2002;118(2):145-54; quiz 154, 208
Date
2002
Language
Finnish
Publication Type
Article
Keywords
Anti-Arrhythmia Agents - therapeutic use
Catheter Ablation - methods
Humans
Risk factors
Severity of Illness Index
Ventricular Premature Complexes - diagnosis - drug therapy - surgery
PubMed ID
12229109 View in PubMed
Less detail

Impaired negative chronotropic response to adenosine in patients with inappropriate sinus tachycardia.

https://arctichealth.org/en/permalink/ahliterature45987
Source
J Cardiovasc Electrophysiol. 2002 Jun;13(6):557-62
Publication Type
Article
Date
Jun-2002
Author
Aino-Maija Still
Heikki V Huikuri
K E Juhani Airaksinen
M Juhani Koistinen
Raimo Kettunen
Juha Hartikainen
Raul D Mitrani
Agustin Castellanos
Robert J Myerburg
M J Pekka Raatikainen
Author Affiliation
Department of Internal Medicine, University of Oulu, Finland.
Source
J Cardiovasc Electrophysiol. 2002 Jun;13(6):557-62
Date
Jun-2002
Language
English
Publication Type
Article
Keywords
Adenosine - administration & dosage - pharmacology
Adrenergic beta-Antagonists - administration & dosage - pharmacology
Adult
Anti-Arrhythmia Agents - administration & dosage - pharmacology
Comparative Study
Depression, Chemical
Dose-Response Relationship, Drug
Electrocardiography
Electrophysiologic Techniques, Cardiac
Female
Finland
Florida
Heart Atria - drug effects
Heart Conduction System - drug effects
Heart Rate - drug effects
Humans
Injections, Intravenous
Male
Middle Aged
Research Support, Non-U.S. Gov't
Tachycardia, Sinus - drug therapy
Time Factors
Treatment Outcome
Abstract
INTRODUCTION: Adenosine is an endogenous nucleoside that has an important role in the diagnosis and treatment of several cardiac arrhythmias. However, its effects on inappropriate sinus tachycardia (IST) are not well established. METHODS AND RESULTS: In this study, the response to intravenous adenosine (0.1 to 0.15 mg/kg) was studied in 18 patients (age 46+/-15 years) with IST. In a subset of patients (n = 5), the direct effects of adenosine were assessed during pharmacologic beta-adrenergic and cholinergic blockade. Atrial cycle length (ACL) was measured before adenosine injection, at the time of the greatest cycle length prolongation, and during the maximum rebound acceleration of heart rate. Eighteen subjects (age 46+/-11 years) with normal sinus rhythm undergoing clinically indicated electrophysiologic study served as controls. Adenosine did not terminate IST in any patient. The maximum dose of adenosine prolonged the sinus interval significantly, from 780+/-128 msec to 985+/-225 msec (P
PubMed ID
12108496 View in PubMed
Less detail

Microvolt T-wave alternans during exercise and pacing in patients with acute myocardial infarction.

https://arctichealth.org/en/permalink/ahliterature49634
Source
Pacing Clin Electrophysiol. 2005 Jan;28 Suppl 1:S193-7
Publication Type
Article
Date
Jan-2005
Author
M J Pekka Raatikainen
Vesa Jokinen
Vesa Virtanen
Juha Hartikainen
Antti Hedman
Heikki V Huikuri
Author Affiliation
University of Oulu, Department of Internal Medicine, Division of Cardiology, Oulu, Finland. pekka.raatikainen@oulu.fi
Source
Pacing Clin Electrophysiol. 2005 Jan;28 Suppl 1:S193-7
Date
Jan-2005
Language
English
Publication Type
Article
Keywords
Cardiac Pacing, Artificial
Electrophysiology
Exercise Test
Female
Humans
Male
Middle Aged
Myocardial Infarction - physiopathology - therapy
Research Support, Non-U.S. Gov't
Abstract
Cardiac Arrhythmias and Risk Stratification after Myocardial infarction (CARISMA) is a prospective multicenter trial designed to document the incidence of cardiac arrhythmias after acute myocardial infarction (AMI), and to assess the predictive accuracy of various arrhythmic risk markers. In this substudy of the CARISMA trial, microvolt T-wave alternans (TWA) was assessed with specific equipment 6 weeks after AMI during bicycle exercise, atrial (A) pacing, and simultaneous ventricular and atrial (V + A) pacing in 80 patients with left ventricular ejection fraction (LVEF)
Notes
Comment In: Pacing Clin Electrophysiol. 2005 Oct;28(10):1145; author reply 1145-616221281
PubMed ID
15683495 View in PubMed
Less detail

Prediction of sudden cardiac death: appraisal of the studies and methods assessing the risk of sudden arrhythmic death.

https://arctichealth.org/en/permalink/ahliterature53522
Source
Circulation. 2003 Jul 8;108(1):110-5
Publication Type
Article
Date
Jul-8-2003

Predictors of pocket hematoma in patients on antithrombotic therapy undergoing cardiac rhythm device implantation: insights from the FinPAC trial.

https://arctichealth.org/en/permalink/ahliterature259360
Source
Ann Med. 2014 May;46(3):177-81
Publication Type
Article
Date
May-2014
Author
Wail Nammas
M J Pekka Raatikainen
Petri Korkeila
Juha Lund
Antti Ylitalo
Pasi Karjalainen
Vesa Virtanen
Ulla-Maija Koivisto
Seppo Utriainen
Tuija Vasankari
Juhani Koistinen
K E Juhani Airaksinen
Source
Ann Med. 2014 May;46(3):177-81
Date
May-2014
Language
English
Publication Type
Article
Keywords
Aged
Aged, 80 and over
Anticoagulants - administration & dosage - adverse effects
Aspirin - adverse effects
Female
Finland - epidemiology
Hematoma - etiology
Humans
Incidence
Male
Middle Aged
Pacemaker, Artificial
Platelet Aggregation Inhibitors - adverse effects
Postoperative Complications - chemically induced - epidemiology
Prosthesis Implantation - adverse effects
Randomized Controlled Trials as Topic
Abstract
The FinPAC trial showed that the strategy of uninterrupted oral anticoagulation (OAC) was non-inferior to interrupted OAC for the primary outcome of bleeding and thromboembolic complications in patients undergoing cardiac rhythm management device (CRMD) implantation.
We conducted a post hoc analysis of the FinPAC data to explore the incidence and predictors of significant (> 100 cm(2)) pocket hematoma after CRMD implantation among the study population (n = 447). A total of 213 patients were on OAC, 128 were on aspirin, and 106 on no antithrombotic therapy.
The incidence of significant pocket hematoma during hospital stay was significantly higher among patients using OAC (5.6%) and aspirin (5.5%) than in those with no antithrombotic medications (0.9%), but only one patient (0.8%) in the aspirin group needed revision of hematoma. Two patients (0.9%) in the OAC group and one (0.8%) in the aspirin group needed blood products. In multivariable regression analysis, no pre- procedural features predicted the significant hematoma in any of the groups.
Clinically significant pocket hematoma is a rare complication after CRMD implantation in patients with ongoing therapeutic OAC. The incidence of significant pocket hematoma formation is similar in patients using OAC and those using aspirin.
PubMed ID
24785546 View in PubMed
Less detail

The quality of warfarin therapy and CHA2DS2-VASc score associate with the incidence of myocardial infarction and cardiovascular outcome in patients with atrial fibrillation: data from the nationwide FinWAF Registry.

https://arctichealth.org/en/permalink/ahliterature297618
Source
Eur Heart J Cardiovasc Pharmacother. 2018 10 01; 4(4):211-219
Publication Type
Journal Article
Research Support, Non-U.S. Gov't
Date
10-01-2018
Author
M J Pekka Raatikainen
Tero Penttilä
Pasi Korhonen
Juha Mehtälä
Riitta Lassila
Mika Lehto
Author Affiliation
Department of Cardiology, Heart and Lung Center, Helsinki University Hospital, Haartmaninkatu 4, Helsinki, Finland.
Source
Eur Heart J Cardiovasc Pharmacother. 2018 10 01; 4(4):211-219
Date
10-01-2018
Language
English
Publication Type
Journal Article
Research Support, Non-U.S. Gov't
Keywords
Adolescent
Adult
Aged
Aged, 80 and over
Anticoagulants - adverse effects - therapeutic use
Atrial Fibrillation - blood - diagnosis - drug therapy - mortality
Blood Coagulation - drug effects
Drug Monitoring - methods
Female
Finland - epidemiology
Humans
Incidence
International Normalized Ratio
Male
Middle Aged
Myocardial Infarction - diagnosis - epidemiology - mortality - prevention & control
Quality Indicators, Health Care
Registries
Retrospective Studies
Risk factors
Time Factors
Treatment Outcome
Warfarin - adverse effects - therapeutic use
Young Adult
Abstract
The impact of the quality of warfarin therapy on cardiovascular outcomes excluding stroke is largely unknown. The aims of this study were to evaluate the association between the warfarin control and the incidence and outcome of myocardial infarction (MI) and to validate the predictive value of the CHA2DS2-VASc score for MI in atrial fibrillation (AF) patients taking warfarin.
The nationwide FinWAF Registry consists of 54?568 AF patients (mean age 73.31?±?10.7?years, 52% men) taking warfarin. The quality of warfarin therapy was assessed continuously by calculating the time in therapeutic range within a 60-day window using the Rosendaal method (TTR60). Adjusted Cox proportional hazards models were prepared for the incidence of MI and cardiovascular mortality in six different TTR60 categories. During the 3.2?±?1.6?years of follow-up, the annual incidence of MI (95% confidence interval) was 3.3% (3.0-3.5%), 2.9% (2.6-3.3%), 2.4% (2.1-2.7%), 1.9% (1.7-2.2%), 1.7% (1.5-2.0%), and 1.2% (1.1-1.3%) among patients with TTR60 80%, respectively. Well-managed warfarin therapy (TTR60?>?80%) was associated also with a lower cardiovascular mortality, whereas a high CHA2DS2-VASc score correlated with poor outcome.
Cardiovascular outcome was superior among AF patients with good warfarin control and in those with a low CHA2DS2-VASc score. The inverse association between the TTR60 and incidence of MI and cardiovascular mortality indicate that in AF patients the quality of warfarin therapy is critical not only for prevention of stroke but also with regard to cardiovascular outcome.
PubMed ID
29514184 View in PubMed
Less detail

Relationship between the frequency of paroxysmal episodes of atrial fibrillation and pulmonary venous flow pattern.

https://arctichealth.org/en/permalink/ahliterature53626
Source
Europace. 2003 Jan;5(1):17-23
Publication Type
Article
Date
Jan-2003
Author
K S Lindgren
M J Pekka Raatikainen
K E Juhani Airaksinen
H V Huikuri
Author Affiliation
University of Oulu, Department of Internal Medicine, Oulu University Hospital, Oulu, Finland.
Source
Europace. 2003 Jan;5(1):17-23
Date
Jan-2003
Language
English
Publication Type
Article
Keywords
Atrial Fibrillation - physiopathology - ultrasonography
Atrial Function, Left - physiology
Echocardiography
Electrocardiography
Female
Humans
Male
Middle Aged
Pulmonary Circulation - physiology
Pulmonary Veins - physiopathology
Abstract
AIMS: Chronic atrial fibrillation causes mechanical remodelling of the atria, but it is uncertain whether self-terminating episodes of paroxysmal atrial fibrillation (PAF) alter atrial mechanical function during normal sinus rhythm. This study was designed to assess the relationship between the frequency of symptomatic arrhythmic episodes and pulmonary venous flow (PVF) pattern among patients with PAF. METHODS AND RESULTS: The effect of symptomatic arrhythmic episodes on PVF was studied in 85 patients with lone PAF (age 48+/-8 years, 66 men). PVF was measured with transthoracic echocardiography during sinus rhythm. Adequate recordings of PVF were achieved in 81 (95%) patients. Peak systolic PVF had an inverse correlation (r=-0.35, P=0.002) with the frequency of PAF episodes. The peak systolic PVF was 76+/-14 cm/s vs 62+/-12 cm/s (P=0.008) among the quartiles with the most and the least frequent episodes of PAF, respectively. There were no significant differences in the other echocardiographic measurements or demographic variables. CONCLUSIONS: Frequent arrhythmic episodes significantly diminished systolic PVF among patients with PAF, suggesting that PAF results in gradual mechanical remodelling of the atrium, which may favour recurrence and perpetuation of AF and/or formation of atrial thrombus.
PubMed ID
12504636 View in PubMed
Less detail

8 records – page 1 of 1.